{
    "nct_id": "NCT03336333",
    "official_title": "An International, Phase 3, Open-Label, Randomized Study of BGB-3111 Compared With Bendamustine Plus Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL)",
    "inclusion_criteria": "* Unsuitable for chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab (FCR)\n* Confirmed diagnosis of CD20-positive CLL or SLL, requiring treatment\n* Measurable disease by imaging\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2\n* Life expectancy ≥ 6 months\n* Adequate bone marrow function\n* Adequate renal and hepatic function\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Previous systemic treatment for CLL/SLL\n* Requires ongoing need for corticosteroid treatment\n* Known prolymphocytic leukemia or history of or suspected Richter's transformation.\n* Clinically significant cardiovascular disease\n* Prior malignancy within the past 3 years, except for curatively treated basal or squamous cell skin cancer, non-muscle-invasive bladder cancer, carcinoma in situ of the cervix of breast, or localized Gleason score 6 prostate cancer\n* History of severe bleeding disorder\n* History of stroke or intracranial hemorrhage within 6 months before the first dose of study drug\n* Severe or debilitating pulmonary disease\n* Inability to swallow capsules or disease affecting gastrointestinal function\n* Active infection requiring systemic treatment\n* Known central nervous system involvement by leukemia or lymphoma\n* Underlying medical condition that will render the administration of study drug hazardous or obscure interpretation of toxicity or AEs\n* Known infection with human immunodeficiency virus (HIV) or active hepatitis B or C infection\n* Major surgery ≤ 4 weeks prior to start of study treatment\n* Pregnant or nursing females\n* Vaccination with live vaccine within 35 days prior to the first dose of study drug.\n* Ongoing alcohol or drug addiction\n* Known hypersensitivity to zanubrutinib, bendamustine, rituximab, or venetoclax (as applicable) or any other ingredients of the study drugs\n* Requires ongoing treatment with strong cytochrome P450 (CYP3A) inhibitor or inducer\n* Concurrent participation in another therapeutic clinical study\n\nNOTE: Other protocol defined Inclusion/Exclusion criteria may apply.",
    "miscellaneous_criteria": "Key"
}